Autoimmune psychosis
In The Lancet Psychiatry, Thomas A Pollak and colleagues report their consensus on diagnosis and management of patients with psychosis of possible, probable, or definite autoimmune cause. 1 Although similar to other criteria for autoimmune encephalitis, autoimmune psychosis rarely presents as an isolated treatable entity.
Previous iterations of criteria for formes fruste of autoimmune encephalitis include those for autoimmune dementia and autoimmune epilepsy-entities proven to be treatment-responsive within 12 months of onset. 2,3 Autoimmune dementia is an operational term for patients with immunotherapy response-confirmed rapidly progressive cognitive decline without delirium or seizures (mimicking Creuzfeldt-Jakob disease or neurodegenerative dementia). 56 (78%) of our 72 suspected cases had objective improvements in neuropsychometric or bedside cognitive measures. 2 One third of patients had been diagnosed previously with degenerative dementia. 2 Autoimmune epilepsy encompasses patients presenting with seizures, without other encephalitic features. 22 (81%) of our 27 cases were immunotherapy responsive (all had >50% seizure reduction, most were Lgi1 antibody positive, which is encephalitis specific, even if detected in serum only). 3 By contrast, Pollak and colleagues provide little cohort-based data to support criteria for isolated autoimmune psychosis as distinct from autoimmune encephalitis. 1 Accurate neurological history should distinguish rare cases of early affective symptom-predominant N-methyl-D-aspartate receptor (NMDAR) encephalitis from primary psychosis. 4 In addition, in 2015, we reported a hospital-based psychiatric cohort of 225 patients; 24 had an autoimmune cause. 5 12 had NMDAR encephalitis (antibody positive in cerebrospinal fluid), and 12 had other paraclinical findings supportive of autoimmunity. None of the patients had a phenotype resembling schizophrenia. Mood symptoms were prominent (80%), and usually preceded psychosis (present in 58%). All had prominent cognitive symptoms, a non-tardive movement disorder, or both, from the outset. All 12 patients with NMDAR encephalitis had early speech and language disorders, 75% became catatonic (not present among the other 12 patients). In our experience, multimodal neuropsychiatric presentations 2 are easily distinguishable from the typical psychiatric referral to our autoimmune neurology clinic: young adults with schizophreniform illnesses, without additional features. Some patients with atypical phenotypes or antipsychotic resistance have received immunotherapy at the behest of distraught parents after counselling of treatment risks. We have been unsuccessful in helping those patients, and all are typically diagnosed with schizophrenia by our psychiatric colleagues. We fear that Pollak and colleagues' consensus will generate the expectation of immunotherapeutic cure for common idiopathic schizophreniform illnesses 1 The general autoimmune predilection among affective disorder cohorts (such as schizophrenia) supports immune-mediated injury during CNS development as risk for primary psychiatric illness later in life, by which time immune therapyresponsiveness has vanished. AM reports grants from Alexion, Grifols, and Euroimmun; and has patents pending for Septin-5-IgG, PDE10A-IgG, MAP1B-IgG, and GFAP-IgG. DD reports consulting fees paid to his employer from Astellas Research Institute of America. EF is principal investigator of a randomised placebo-controlled clinical trial of inebilizumab (CD19 inhibitor) in neuromyelitis optica spectrum disorders funded by MedImmune/Viela Bio and recieves reimbursement for research trial costs. SP reports grants, personal fees, non-financial support, and other from Alexion Pharmaceuticals and MedImmune; grants from Grifols, National Institutes of Health, and Autoimmune Encephalitis Alliance; consulting fees I n The Lancet Psychiatry, Thomas A Pollak and colleagues used criteria of paraneoplastic and autoimmune encephalitis to try to establish autoimmune psychosis as an identity by itself. 1 The most compelling reason they provided was that there are patients "having atypical, mild, or attenuated forms of autoimmune encephalitis".
The prominent neuronal surface antibodies found in patients with psychosis are those against the N-methyl-D-aspartate receptor (NMDAR), which block this receptor and cause psychosis in addition to symptoms associated with encephalitis. Only a small proportion of patients with anti-NMDAR encephalitis
